See more : Clifton Mining Company (CFTN) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Path Holdings, Inc. (BPTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Path Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Megacable Holdings, S. A. B. de C. V. (MEGACPO.MX) Income Statement Analysis – Financial Results
- C-Link Squared Limited (1463.HK) Income Statement Analysis – Financial Results
- Yuhan Corporation (000105.KS) Income Statement Analysis – Financial Results
- Foremost Lithium Resource & Technology Ltd. (FRRSF) Income Statement Analysis – Financial Results
- Fantasy Aces Daily Fantasy Sports Corp. (FASDF) Income Statement Analysis – Financial Results
Bio-Path Holdings, Inc. (BPTH)
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.44K | 43.81K | 59.45K | 79.31K |
| Cost of Revenue | 178.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 0.00 | 0.00 | 201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.11K | 37.77K | 43.88K | 55.42K |
| Gross Profit | -178.00K | -178.00K | -161.00K | -151.00K | -230.00K | -426.00K | 37.00K | 13.00K | -201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.67K | 6.05K | 15.58K | 23.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9.05% | 13.80% | 26.20% | 30.13% |
| Research & Development | 11.61M | 9.17M | 5.91M | 6.58M | 4.59M | 4.60M | 5.48M | 5.47M | 3.02M | 1.83M | 1.63M | 1.60M | 1.14M | 1.14M | 480.26K | 333.47K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.11M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 0.00 | 704.88K | 1.31M | 587.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 123.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.24M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 1.22M | 704.88K | 1.31M | 587.16K | 107.44K | 141.31K | 82.53K | 78.16K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 0.00 | 0.00 | 196.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182.98K | 171.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 107.44K | 141.31K | 82.53K | 78.16K |
| Cost & Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 127.55K | 179.08K | 126.40K | 133.58K |
| Interest Income | 36.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 9.00K | 12.00K | 17.67K | 22.63K | 4.04K | 779.00 | 2.91K | 1.30K | 3.38K | 41.06K | 0.00 | 541.00 | 132.00 | 1.35K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.94K | 13.08K | 17.62K | 13.26K |
| Depreciation & Amortization | 82.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 411.00K | 204.00K | 201.76K | 170.91K | 160.63K | 185.27K | 211.71K | 197.27K | 182.98K | 171.95K | 1.68K | 2.72K | 3.03K | 3.06K |
| EBITDA | -15.76M | -13.69M | -10.28M | -10.73M | -8.37M | -8.16M | -8.56M | -8.27M | -5.27M | -4.35M | -3.11M | -2.40M | -2.15M | -1.88M | -1.79M | -2.68M | -107.44K | -132.00K | -63.79K | -49.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,348.65% | -76,800.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -973.44% | -301.30% | -107.30% | -62.85% |
| Operating Income | -15.84M | -13.90M | -10.44M | -10.91M | -8.69M | -8.59M | -8.97M | -8.48M | -5.48M | -4.54M | -3.27M | -2.58M | -2.37M | -2.33M | -1.97M | -2.89M | -109.11K | -135.27K | -66.95K | -54.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24,232.43% | -65,192.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -591.78% | -308.75% | -112.61% | -68.42% |
| Total Other Income/Expenses | -235.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 1.94M | 1.73M | 18.21K | 22.05K | 3.23K | -344.86K | 2.27K | -232.43K | 3.38K | 41.06K | 56.67K | -12.54K | -17.49K | -11.91K |
| Income Before Tax | -16.08M | -13.87M | -10.44M | -10.88M | -8.60M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.45K | -147.81K | -84.44K | -66.17K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.44% | -337.37% | -142.02% | -83.43% |
| Income Tax Expense | 0.00 | -33.00K | -3.00K | -26.00K | -94.00K | -608.00K | -1.94M | -1.73M | 0.00 | -22.30K | -3.23K | -142.00 | -2.27K | 232.43K | 0.00 | 2.85M | 100.00 | 100.00 | 100.00 | 100.00 |
| Net Income | -16.08M | -13.84M | -10.44M | -10.86M | -8.51M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.55K | -147.91K | -84.54K | -66.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.99% | -337.60% | -142.19% | -83.56% |
| EPS | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| EPS Diluted | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| Weighted Avg Shares Out | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
| Weighted Avg Shares Out (Dil) | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President...
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its...
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the...
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that...
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002. This clinical trial is focusing on the use of BP1002 as a treatment for refractory/relapsed acute...
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell's Ability to Produce Cancer Enabling Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell's Ability to Produce Cancer Enabling...
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform
Source: https://incomestatements.info
Category: Stock Reports